What are the building blocks in the EU Health Union?
Find out in our new collection
Explaining your work in a clear, accessible way - the key public health message box
Click for more info
Looking at the benefits and risks, efficacy and vaccine effectiveness
Find them in our COVID-19 vaccines collectionChanging urban environments and effects on infectious diseases Submit your articles now
Eurosurveillance
Since 1995, Eurosurveillance has provided the European public health community with an open-access platform to exchange relevant findings on communicable disease surveillance, prevention and control. A weekly, electronic, peer-reviewed publication, Eurosurveillance aims to provide timely facts and guidance for public health professionals and decision-makers in the field of infectious disease to facilitate the implementation of effective prevention and control measures. Impact factor: 19. More...
Latest Issue: Volume 28, Issue 49, 07 December 2023 Latest Issue RSS feed
- Editorial
- Rapid communication
-
-
-
Genomic characterisation of respiratory syncytial virus: a novel system for whole genome sequencing and full-length G and F gene sequences
To advance our understanding of respiratory syncytial virus (RSV) impact through genomic surveillance, we describe two PCR-based sequencing systems, (i) RSVAB-WGS for generic whole-genome sequencing and (ii) RSVAB-GF, which targets major viral antigens, G and F, and is used as a complement for challenging cases with low viral load. These methods monitor RSV genetic diversity to inform molecular epidemiology, vaccine effectiveness and treatment strategies, contributing also to the standardisation of surveillance in a new era of vaccines.
-
-
-
Early lessons from the implementation of universal respiratory syncytial virus prophylaxis in infants with long-acting monoclonal antibodies, Galicia, Spain, September and October 2023
More LessA monoclonal antibody for universal respiratory syncytial virus prophylaxis in infants has recently been licensed. We share our experiences of integrating nirsevimab into the regional immunisation programme in Galicia, Spain. After a 3-week hospital-based immunisation campaign with flexible individualised appointments and educational activities, nirsevimab uptake was 97.5% in the high-risk group, 81.4% in the catch-up group and 92.6% in infants born during the campaign. This successful implementation strategy can serve as a model and may inform other countries’ programmatic deliberations.
-
-
-
A cluster of autochthonous dengue transmission in the Paris region – detection, epidemiology and control measures, France, October 2023
Nelly Fournet , Nathalie Voiry , Julian Rozenberg , Clément Bassi , Caroline Cassonnet , Anaïs Karch , Guillaume Durand , Gilda Grard , Gabriela Modenesi , Stevens-Boris Lakoussan , Nicolas Tayliam , Marta Zatta , Sébastien Gallien , on behalf of the investigation team , Harold Noël , Ségolène Brichler and Arnaud TarantolaA cluster of three confirmed autochthonous dengue cases was detected in October 2023 in the Val-de-Marne department neighbouring Paris, France. This marks the northernmost transmission of dengue in Europe reported to date. The epidemiological and microbiological investigations and the vector control measures are described. This event confirms the need for early case detection and response to contain dengue in Europe, especially given the 2024 Summer Olympic and Paralympic Games, when millions of visitors will visit the Greater Paris area.
-
- Top
-
- Research
-
-
-
Factors associated with parental intention to vaccinate their child against influenza, Finland, February to March, 2022: a web-based survey
More LessBackgroundInfluenza vaccination for children aged 6 months to 6 years is included in the national vaccination programme in Finland. Although all vaccines in the programme are free of charge, national coverage of influenza vaccination among children under 3 years and 3–6 years during 2020/21 was 43% and 35% respectively, with regional differences.
AimTo assess factors underlying parental vaccination intention in order to increase influenza vaccine uptake among children.
MethodsWe conducted a web-based survey among parents (n = 17,844) of randomly selected eligible children (aged 6 months–6 years) in February–March 2022 in five Finnish municipalities from regions of high and low coverage. Logistic regressions were used to determine associations between vaccination intention and e.g. sociodemographic factors, attitudes and knowledge. Linkage to the national vaccination register was used to confirm realisation of vaccination intention after the study.
ResultsParticipation rate was 13% (n = 2,322 parents). Influenza knowledge, trust in official information, responding parent’s education level, adherence to the vaccination programme, number of children and changes in attitudes towards vaccination since COVID-19 were all associated with intention to vaccinate. Vaccination intention for children was 64%, and realised vaccination 51%.
ConclusionDespite the low participation rate, both vaccinated and unvaccinated children were represented. Influenza vaccine uptake is not dependent on a single factor. Our results identified the need for open dialogue between parents and healthcare professionals, as the lack of vaccine being offered by healthcare professionals was the most reported reason for not vaccinating.
-
- Top
-
- Miscellaneous
-